Omnicell upgraded to Equal Weight from Underweight at Barclays

Barclays upgraded Omnicell to Equal Weight from Underweight with a price target of $39, up from $26. The company reported solid Q2 results and multiple positive data points provide further conviction on its path forward, the analyst tells investors in a research note. The firm says that while the shares were up 33% post the earnings call, this is merited as the forward story becomes more a function of execution than macro improvements.